AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial

Early Versus Delayed Antiretroviral Therapy and Cerebrospinal Fluid Fungal Clearance in Adults With HIV and Cryptococcal Meningitis

(2013) Gregory P. Bisson et al.   CLINICAL INFECTIOUS DISEASES

Determinants of Mortality in a Combined Cohort of 501 Patients With HIV-Associated Cryptococcal Meningitis: Implications for Improving Outcomes

(2013) Joseph N. Jarvis et al.   CLINICAL INFECTIOUS DISEASES

Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal

(2013) A. Loyse et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacodynamics of Liposomal Amphotericin B and Flucytosine for Cryptococcal Meningoencephalitis: Safe and Effective Regimens for Immunocompromised Patients

(2013) Lucy O'Connor et al.   JOURNAL OF INFECTIOUS DISEASES

Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries

(2013) Angela Loyse et al.   LANCET INFECTIOUS DISEASES

Combination Antifungal Therapy for Cryptococcal Meningitis

(2013) Jeremy N. Day et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Prospective Longitudinal Study of the Clinical Outcomes from Cryptococcal Meningitis following Treatment Induction with 800 mg Oral Fluconazole in Blantyre, Malawi

(2013) Camilla Rothe et al.   PLoS One

A suicide risk screening scale for HIV-infected persons in the immediate post-diagnosis period

(2013) R D Govender et al.   SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE

A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis

(2012) Arthur T. Jackson et al.   AIDS

Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis

(2012) Joseph N. Jarvis et al.   AIDS

Population Pharmacokinetics of Conventional and Intermittent Dosing of Liposomal Amphotericin B in Adults: a First Critical Step for Rational Design of Innovative Regimens

(2012) William W. Hope et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of the Early Fungicidal Activity of High-Dose Fluconazole, Voriconazole, and Flucytosine as Second-Line Drugs Given in Combination With Amphotericin B for the Treatment of HIV-Associated Cryptococcal Meningitis

(2011) A. Loyse et al.   CLINICAL INFECTIOUS DISEASES

British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011

(2011) M Nelson et al.   HIV MEDICINE

Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis

(2011) Conrad K. Muzoora et al.   JOURNAL OF INFECTION

Universal screening of Tanzanian HIV-infected adult inpatients with the serum cryptococcal antigen to improve diagnosis and reduce mortality: an operational study

(2011) Bahati MK Wajanga et al.   Journal of the International AIDS Society

Comparison of 2 Doses of Liposomal Amphotericin B and Conventional Amphotericin B Deoxycholate for Treatment of AIDS‐Associated Acute Cryptococcal Meningitis: A Randomized, Double‐Blind Clinical Trial of Efficacy and Safety

(2010) Richard J. Hamill et al.   CLINICAL INFECTIOUS DISEASES

Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America

(2010) John R. Perfect et al.   CLINICAL INFECTIOUS DISEASES

In-hospital mortality of HIV-infected cryptococcal meningitis patients withC. gattiiandC. neoformansinfection in Gaborone, Botswana

(2010) Katherine T. Steele et al.   MEDICAL MYCOLOGY

Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India

(2010) Shyam Sundar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS

(2009) Benjamin J Park et al.   AIDS

Pharmacokinetics and Buccal Mucosal Concentrations of a 15 Milligram per Kilogram of Body Weight Total Dose of Liposomal Amphotericin B Administered as a Single Dose (15 mg/kg), Weekly Dose (7.5 mg/kg), or Daily Dose (1 mg/kg) in Peripheral Stem Cell Transplant Patients

(2009) P. O. Gubbins et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Phase II Randomized Trial of Amphotericin B Alone or Combined with Fluconazole in the Treatment of HIV‐Associated Cryptococcal Meningitis

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIV‐Associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 Patients

(2009) Tihana Bicanic et al.   CLINICAL INFECTIOUS DISEASES

Combination Flucytosine and High‐Dose Fluconazole Compared with Fluconazole Monotherapy for the Treatment of Cryptococcal Meningitis: A Randomized Trial in Malawi

(2009) Jesse C. Nussbaum et al.   CLINICAL INFECTIOUS DISEASES

Outcomes of Cryptococcal Meningitis in Uganda Before and After the Availability of Highly Active Antiretroviral Therapy

(2008) Andrew Kambugu et al.   CLINICAL INFECTIOUS DISEASES

Dose Response Effect of High‐Dose Fluconazole for HIV‐Associated Cryptococcal Meningitis in Southwestern Uganda

(2008) Nicky Longley et al.   CLINICAL INFECTIOUS DISEASES

High‐Dose Amphotericin B with Flucytosine for the Treatment of Cryptococcal Meningitis in HIV‐Infected Patients: A Randomized Trial

(2008) Tihana Bicanic et al.   CLINICAL INFECTIOUS DISEASES

The Use of HAART Is Associated With Decreased Risk of Death During Initial Treatment of Cryptococcal Meningitis in Adults in Botswana

(2008) Gregory P Bisson et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES